Vidarbha News

DelveInsight Highlights Major Advances, Transformative Therapies, and 120+ Leading Players Wheeling the Influenza Clinical Trial Pipeline Landscape

 Breaking News
  • No posts were found

DelveInsight Highlights Major Advances, Transformative Therapies, and 120+ Leading Players Wheeling the Influenza Clinical Trial Pipeline Landscape

September 03
17:36 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 120+ Leading Players Wheeling the Influenza Clinical Trial Pipeline Landscape

The Influenza Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Influenza treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the pipeline landscape and fostering the potential growth of Influenza therapeutic advancements.

 

Key Takeaways from the Influenza Pipeline Report

  • DelveInsight’s Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment.
  • The leading companies working in the Influenza market include Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc., Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc., BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Emergent, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
  • Promising Influenza Pipeline Therapies in the various stages of development include VX-787 300 mg, Oseltamivir 75 mg, CD388, Seasonal Influenza Vaccine (MF59C.1), Oseltamivir, GSK4382276A Dose level 1, favipiravir, and others.
  • On March 2023, Seqirus announced a study of phase 3 clinical trials for Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV). Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to
  • On July 2023, GlaxoSmithKline announced a study of phase 1 & 2 clinical trials for Flu mRNA. The purpose of this study is to find and confirm the dose and asses the reactogenicity, safety and immune response of GlaxoSmithKline’s (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine (GSK4382276A) candidates administered in healthy younger and older adults (OA).
  • On July 2023, Osivax announced a study of phase 2 clinical trials for OVX836 480µg, Fluarix Tetra, and Afluria Quad. Confirm feasibility of the concomitant administration of the vaccines under normal clinical conditions, i.e. as two separate concomitant injections into opposite arms.
  • On August 2023, Cidara Therapeutics Inc. announced a study of Phase 2 clinical trials for CD388. The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.

 

Request a sample and discover the recent advances in Influenza Treatment Drugs @ Influenza Pipeline Report

 

The Influenza pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Influenza drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Influenza clinical trial landscape.

 

Influenza Overview

Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death.

 

Find out more about Influenza Treatment Drugs @ Drugs for Influenza Treatment

 

Influenza Emerging Drugs Profile

  • mRNA-1010: Moderna
  • SAB-176: SAB Biotherapeutics
  • INNA-051: ENA Respiratory Pty Ltd
  • CODA-VAX H1N1: Codagenix
  • ALVR106: AlloVir

 

Influenza Pipeline Therapeutics Assessment

The Influenza pipeline report proffers an integral view of the Influenza emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Learn more about the emerging Influenza Pipeline Therapies @ Influenza Clinical Trials Assessment

 

Scope of the Influenza Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc., Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc., BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Emergent, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others.
  • Influenza Pipeline Therapies- VX-787 300 mg, Oseltamivir 75 mg, CD388, Seasonal Influenza Vaccine (MF59C.1), Oseltamivir, GSK4382276A Dose level 1, favipiravir, and others.

 

Dive deep into rich insights for new drugs for Influenza treatment, Visit @ Influenza Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Influenza: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Influenza – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. mRNA-1010: Moderna
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. INNA-051: ENA Respiratory Pty Ltd
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. CODA-VAX H1N1: Codagenix
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Influenza Key Companies
  21. Influenza Key Products
  22. Influenza- Unmet Needs
  23. Influenza- Market Drivers and Barriers
  24. Influenza- Future Perspectives and Conclusion
  25. Influenza Analyst Views
  26. Influenza Key Companies
  27. Appendix

 

For further information on the Influenza pipeline therapeutics, reach out @ Influenza Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Categories